Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 30/10/2019
SIETES contiene 92829 citas

 
 
 1 a 20 de 127 siguiente >>
Presentar resultados
Seleccionar todas
1. Cita con resumen
Rojas-Velandia C, Ruiz-Garzón J, Moscoso-Alcina J-C, Vallejos-Narváez A, Castro-Canoa J, Bustos-Martínez Y, Flórez-Cutiva M, Contreras-Muñoz M, Gómez-Gil JC, Calderón-Ospina C-A. Characterization of adverse drug reactions causing admission to an intensive care unit. Br J Clin Pharmacol 2017;83:1134-40. [Ref.ID 101974]
3. Cita con resumen
Patel R, Wilson R, Jackson R, Ball M, Shetty H, Broadbent M, Stewart R, McGuire P, Bhattacharyya S. Association of cannabis use with hospital admission and antipsychotic treatment failure in first episode psychosis: an observational study . BMJ Open 2016;6:e009888. [Ref.ID 100279]
4. Cita con resumen
Collins JM, Raphael KL, Terry C, Cartwright EJ, Pillai A, Anania FA, Farley MM. Hepatitis B virus reactivation during successful treatment of hepatitis C virus with sofosbuvir and simeprevir. Clin Infect Dis 2015;61:1304-6. [Ref.ID 99556]
5. Cita con resumen
Aquino TL, Brice GT, Hayes S, Myers CA, McDowell J, White B, Garten R, Johnston D. Influenza outbreak in a vaccinated population — USS Ardent, February 2014 weekly. Morbidity and Mortality Weekly Report 2014;63:947-9. [Ref.ID 98192]
6. Cita con resumen
Saunders DL, Vanachayangkul P, Lon C, U.S. Army Military Malaria Research Program, National Center for Parasitology Entomology and Malaria Control (CNM), Royal Cambodian Armed Forces. Dihydroartemisinin-piperaquine failure in Cambodia. N Engl J Med 2014;371:484-5. [Ref.ID 97838]
8. Cita con resumen
Anónimo. Orlistat: theoretical interaction with antiretroviral HIV medicines. Drug Safety Update 2014;7:A1. [Ref.ID 97241]
9.Tiene citas relacionadas
Karran E, Hardy J. Antiamyloid therapy for Alzheimer's disease - are we on the right road?. N Engl J Med 2014;370:377-8. [Ref.ID 97062]
10.Tiene citas relacionadas Cita con resumen
Salloway S, Sperling R, Fox NC, Blennow K, Klunk W, Raskind M, Sabbagh M, Honig LS, Porsteinsson AP, Ferris S, Reichert M, Ketter N, Bejadnik B, Guenzler V, Miloslavsky M, Wang D, Lu Y, Lull J, Tudor IC, Liu E, Grundman M, Yuen E, Black R, Brashear R, for the Bapineuzumab 301 and 302 Clinical Trial Investigators. Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease. N Engl J Med 2014;370:322-33. [Ref.ID 97061]
11.Tiene citas relacionadas Cita con resumen
Doody RS, Thomas RG, Farlow M, Iwatsubo T, Vellas B, Joffe S, Kieburtz K, Raman R, Sun X, Aisen PS, Siemers E, Seifert HL, Mohs R, for the Alzheimer's Disease Cooperative Study Steering Committee and the Solanezumab Study Group. Phase 3 of solanezumab in mild-to-moderate Alzheimer's disease. N Engl J Med 2014;370:311-21. [Ref.ID 97060]
12. Cita con resumen
van den Bemt BJF, den Broeder AA, Wolbink G-J, van den Maas A, Hekster YA, van Riel PLCM, Benraad HB, van den hoogen FHJ. The combined use of disease activity and infliximab serum trough concentrations for early prediction of (non-)response to infliximab in rheumatoid arthritis. Br J Clin Pharmacol 2013;76:939-45. [Ref.ID 96632]
13.
Moore A, Derry S, Eccleston C, Kalso E. Expect analgesic failure; pursue analgesic success. BMJ 2013;346:19-21. [Ref.ID 95915]
14.Enlace a cita original Cita con resumen
Moreno Izco L. Tratamiento antipsicótico ante el fracaso de la primera línea de tratamiento: ¿subir dosis, cambio de fármaco, asociar antipsicóticos?. Boletín de Información Farmacoterapéutica de Navarra 2012;20:1-11. [Ref.ID 94076]
15. Cita con resumen
Kuehn BM. Hepatitis drug reduces effects of HIV medications. JAMA 2012;307:2138. [Ref.ID 93067]
16.Tiene citas relacionadas Cita con resumen
Anónimo. Tamoxifen and CYP 2D6 inhibitors: caution. Prescrire Int 2011;20:182-4. [Ref.ID 91095]
17.Tiene citas relacionadas Cita con resumen
Herbst R, Ansari R, Bustin F, Flynn P, Hart L, Otterson GA, Vlahovic G, Soh CH, O'Connor P, Hainsworth J. Efficacy of bevacizumab plus erlotinib versus erlotinib alone in advanced non-small-cell lung cancer after failure of standard first-line chemotherapy (Be Ta): a double-blind, placebo-controlled, phase 3 trial. Lancet 2011;377:1846. [Ref.ID 90855]
18.Tiene citas relacionadas
Sculier JP, Meert A-P, Berghmans T. Salvage with erlotinib plus bevacizumab: not in NSCLC. Lancet 2011;377:1810-2. [Ref.ID 90842]
19.Tiene citas relacionadas Cita con resumen
Anónimo. Tamoxifène et inhibiteurs de l'isoenzyme CYP 2D6: prudence. Prescrire 2011;31:190-2. [Ref.ID 90306]
20.
Esposito K, Bellastella G, Giugliano D. When metfomin fails in type 2 diabetes mellitus. Arch Intern Med 2011;171:365-6. [Ref.ID 90290]
Seleccionar todas
 
 1 a 20 de 127 siguiente >>